|
A phase 1 study of CD38-bispecific antibody (XmAb18968) for patients with CD38 expressing relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia. |
|
Guru Subramanian Guru Murthy |
Honoraria - Cardinal Health; Gilead Sciences; TG therapeutics |
Consulting or Advisory Role - Cancer Expert Now; Market Plus; Putnam Associates; Qessential Medical Marketing Research; SmartAnalyst; techspert.io |
Research Funding - Xencor |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Adaptive Biotechnologies; Pfizer; Takeda |
Travel, Accommodations, Expenses - Adaptive Biotechnologies |
(OPTIONAL) Uncompensated Relationships - Abbvie; Amgen; Kite/Gilead |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
Honoraria - BeiGene; Gilead Sciences; Pharmacyclics/Janssen; Spectrum/Acrotech |
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen; Bristol-Myers Squibb/Celgene; Kite, a Gilead company; Novartis; Pfizer; Pfizer; Precision Biosciences |
Research Funding - Incyte; Jazz Pharmaceuticals (Inst); Kite/Gilead |
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Janssen; Kite, a Gilead company; Novartis; Pfizer; Seagen; Stemline Therapeutics |
|
|
|
Consulting or Advisory Role - Adaptive Biotechnologies; agios; GlaxoSmithKline; Jazz Pharmaceuticals; Kite, a Gilead company; Kura Oncology; morphosys; Pfizer; SERVIER |
Patents, Royalties, Other Intellectual Property - Royalties for a chapter in Up to Date |
Travel, Accommodations, Expenses - Pfizer |
|
|
Consulting or Advisory Role - Abbvie/Genentech; Bristol-Myers Squibb; Jazz Pharmaceuticals; Novartis; Pfizer; Syndax; Takeda |
Speakers' Bureau - Abbvie; Celgene; Jazz Pharmaceuticals; Novartis |
Research Funding - Novartis (Inst); Takeda (Inst) |